This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ioannidis, J. P. A. Articles by Katritsis, D. G. Search for Related Content PubMed PubMed Citation Articles by Ioannidis, J. P. A. Articles by Katritsis, D. G.

Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention

John P. A. Ioannidis, MD^*,*, Evangelia Karvouni, MD and Demosthenes G. Katritsis, MD, PhD, FACC

^* Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine and the Biomedical Research Institute, Foundation for Research and Technology, Hellas– Ioannina, Greece
Division of Clinical Care Research, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
Department of Cardiology, Athens Euroclinic, Athens, Greece

View larger version (27K): [in a new window]   Figure 1 Relative risk of death with various creatine kinase-MB isoenzyme (CK-MB) elevations. Each study is shown by the risk ratio estimate and the corresponding 95% confidence interval. Also shown is the summary estimate for all studies. (A) One- to five-fold elevation versus normal CK-MB. (B) Three- to five-fold elevation versus normal CK-MB. (C) Three- to five-fold elevation versus normal CK-MB. (D) >5-fold elevation versus normal CK-MB.